Breakthrough Drug Targets 'Undruggable' Proteins in Pancreatic Cancer
A groundbreaking clinical trial has demonstrated that the drug daraxonrasib effectively targets a family of mutant proteins previously considered 'undruggable' in patients with deadly pancreatic cancer. Published in the New England Journal of Medicine and reported by Nature, the study reveals that participants treated with this new therapy experienced significantly longer survival rates compared to historical standards. The drug works by blocking the activity of specific mutant proteins that drive tumor growth, leading to either the shrinkage of tumors or a halt in their progression for many individuals involved in the small-scale trial. This development marks a significant milestone in oncology, offering new hope for treating one of the most aggressive and hard-to-treat forms of cancer. The findings suggest that targeting these elusive proteins is now a viable therapeutic strategy, potentially transforming treatment protocols for pancreatic cancer patients who have historically faced limited options and poor prognoses. Further large-scale studies are anticipated to validate these promising initial results.
Wire timeline
Breakthrough Drug Targets 'Undruggable' Proteins in Pancreatic Cancer
A groundbreaking clinical trial has demonstrated that the drug daraxonrasib effectively targets a family of mutant proteins previously considered 'undruggable' in patients with deadly pancreatic cancer. Published in the New England Journal of Medicine and reported by Nature, the study reveals that participants treated with this new therapy experienced significantly longer survival rates compared to historical standards. The drug works by blocking the activity of specific mutant proteins that drive tumor growth, leading to either the shrinkage of tumors or a halt in their progression for many individuals involved in the small-scale trial. This development marks a significant milestone in oncology, offering new hope for treating one of the most aggressive and hard-to-treat forms of cancer. The findings suggest that targeting these elusive proteins is now a viable therapeutic strategy, potentially transforming treatment protocols for pancreatic cancer patients who have historically faced limited options and poor prognoses. Further large-scale studies are anticipated to validate these promising initial results.
Nature